TY - JOUR
T1 - Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases
AU - Pejovic, Tanja
AU - Abate, Pierre Valérien
AU - Ma, Hongli
AU - Thiessen, Jaclyn
AU - Corless, Christopher L.
AU - Peterson, Abigail
AU - Allard-Chamard, Hugues
AU - Labrie, Marilyne
N1 - Funding Information:
This project was supported by the Adelson Medical Research Foundation, the Sherie Hildreth Ovarian Cancer Foundation. P-VA is supported by Grant 878491 from the Cancer Research Society and by Ovarian Cancer Canada/OvCAN through funding provided by Health Canada.
Publisher Copyright:
Copyright © 2022 Pejovic, Abate, Ma, Thiessen, Corless, Peterson, Allard-Chamard and Labrie.
PY - 2022/5/25
Y1 - 2022/5/25
N2 - Between 2% and 6% of epithelial ovarian cancer (EOC) patients develop brain metastases (brain mets), which are incurable and invariably result in death. This poor outcome is associated with a lack of established guidelines for the detection and treatment of brain mets in EOC patients. In this study, we characterize an unusual case of low-grade serous ovarian carcinoma (LGSOC) that metastasized to the brain. Using a spatially oriented single-cell proteomics platform, we compared sequential biopsies of a primary tumor with a peritoneal recurrence and brain mets. We identified several targetable oncogenic pathways and immunosuppressive mechanisms that are amplified in the brain mets and could be involved in the progression of LGSOC to the brain. Furthermore, we were able to identify cell populations that are shared between the primary tumor and the brain mets, suggesting that cells that have a propensity for metastasis to the brain could be identified early during the course of disease. Taken together, our findings further a path for personalized therapeutic decisions in LGSOC.
AB - Between 2% and 6% of epithelial ovarian cancer (EOC) patients develop brain metastases (brain mets), which are incurable and invariably result in death. This poor outcome is associated with a lack of established guidelines for the detection and treatment of brain mets in EOC patients. In this study, we characterize an unusual case of low-grade serous ovarian carcinoma (LGSOC) that metastasized to the brain. Using a spatially oriented single-cell proteomics platform, we compared sequential biopsies of a primary tumor with a peritoneal recurrence and brain mets. We identified several targetable oncogenic pathways and immunosuppressive mechanisms that are amplified in the brain mets and could be involved in the progression of LGSOC to the brain. Furthermore, we were able to identify cell populations that are shared between the primary tumor and the brain mets, suggesting that cells that have a propensity for metastasis to the brain could be identified early during the course of disease. Taken together, our findings further a path for personalized therapeutic decisions in LGSOC.
KW - brain metastases
KW - cyclic immunofluorescence
KW - low-grade serous ovarian cancer
KW - single-cell proteomics
KW - spatial analysis
UR - http://www.scopus.com/inward/record.url?scp=85131862141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131862141&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.903806
DO - 10.3389/fonc.2022.903806
M3 - Article
AN - SCOPUS:85131862141
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 903806
ER -